Señales en vivo de TBP.TO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 mar 2023 @ 15:59):

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology...

Stats
Volumen de hoy	476 110
Volumen promedio	0.00
Capitalización de mercado	10.58M
EPS	$0 ( 2023-11-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.313
ATR14	$0 (0.00%)

Volumen Correlación

Largo: 0.06 (neutral)

Corto: 0.00 (neutral)

Signal:(52.174) Neutral

TETRA BIO PHARMA INC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TETRA BIO PHARMA INC Correlación - Moneda/Commodity

0.00
( neutral )

0.63
( weak )

-0.14
( neutral )

TETRA BIO PHARMA INC Finanzas

Annual	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.202

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.202

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.100

FY	2019
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0800

Financial Reports:

No articles found.

TETRA BIO PHARMA INC

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.